Loading...
Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
BACKGROUND: Crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with anaplastic lymphoma kinase-positive (alk+) non-small cell lung cancer (nsclc), but little information is available on its use and outcomes in real-world settings. We therefore assessed treatment p...
Na minha lista:
| Udgivet i: | Curr Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Multimed Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832290/ https://ncbi.nlm.nih.gov/pubmed/29507494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3723 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|